QPS further enhances its global medical, regulatory, and biotech CRO services capabilities

QPS, a leading global contract research organization (CRO), continues to expand and align its full service preclinical, bioanalysis, and clinical capabilities with enhanced offerings across the medical, regulatory and biotech divisions. With these enhanced global capabilities, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving Biotech’s customized needs.

QPS has carefully selected 3 new Executives to lead this transformation. Heather Messenger, Sr. Vice President, Head of GlobalBiotech Services, Sarah Cross, Executive Director, Head of Global Medical Affairs, and Kimberley Buytaert-Hoefen, Executive Director, Head of Global Regulatory Affairs. Together they will further strengthen global collaboration, enabling agile and flexible clinical operations, stronger customer relationships, and enhanced strategic partnerships.

Ms. Messenger who joins QPS with over 26 years of experience across Biotech, BioPharma, and CRO sectors, will be taking the lead in expanding QPS clinical execution services and capabilities, with a focus on Biotech clients. She has worked in more than 7 startup companies across both biotech/biopharma bringing a deep understanding of the industry and the offerings necessary for a CRO partner to help accelerate clinical development activities.

Dr. Cross brings over 14 years of experience in medical affairs, across the areas of immunology, oncology, and women's health focused clinical research, asset development, product launch, diagnostics, and technology transfer in the Pharma, Biotech, and CRO industries. Her strong medical affairs expertise across the drug development lifecycle will support the growth and development of the Global Medical Affairs Team at QPS, leading to best-in-class strategic partnerships, clinical trial support, medical communication, medical education, and evidence generation for Pharma and Biotech clients.

Dr. Buytaert-Hoefen is a seasoned professional with 25 years of preclinical and clinical regulatory experience, supporting drug development in the commercial pharmaceutical and biotech, gene and cellular therapy, and medical device industries. As a former FDA investigator, she performed surveillance for cause, pre-approval establishment and post-marketing adverse drug experience reporting inspections. Buytaert-Hoefen will expand QPS capabilities by providing Regulatory expertise to global drug development programs.

According to John Musante, QPS Executive VP, Global Head of Clinical Research Services, “These enhanced capabilities and newly appointed leadership positions will further bolster our Pharma and Biotech clients’ abilities to develop drugs in an agile and flexible manner, by fully integrating these services into the custom-built QPS drug development packages.”

QPS is fully committed to partnering with the Biotech and Pharmaceutical industry to support global drug development from preclinical through post-marketing needs. These new executives will ensure that QPS has the skills and capabilities to fully implement global Pharma and Biotech drug development projects.

Want the latest science news straight to your inbox? Become a SelectScience member for free today >>